On October 13, 2026, New York-based virtual women's health company Allara announced a $30 million round, bringing total funding to $75 million. Existing investors Index Ventures and GV increased their commitments, and Camino Partners, Foreground and Family Fund joined as new backers (AlleyWatch; Future Fem Health). One Axios Pro headline put the raise at $39 million. Both the company's own interview and the trade coverage say $30 million, so we use that figure.

Why It Matters

Women's health telehealth is splitting into two models. The cash-pay subscription model, which Hims & Hers just [took to Australia with menopause as the entry point](/stories/hims-australia-pilot-rebrand), sells convenience. The insurance-covered model sells continuity of care for chronic conditions. Allara is betting payers will cover the second, and a $75M total suggests investors agree. The service list also shows how hormonal care, GLP-1s, HRT and sexual health (BV, STI testing) are converging into one subscription relationship, the same convergence driving [Clue's Get Care marketplace](/stories/clue-get-care-in-app-care-marketplace) and [Google's stake in Flo](/stories/google-flo-health-partnership). For sexual-wellness brands, the opportunity is a referral layer. Platforms that treat perimenopause and PMOS see the libido, dryness and pain complaints that follow, and these are the categories where lubricants, vaginal moisturisers and pelvic-health devices are looking for clinical channels. The "largest dataset in women's health" ambition also brings scrutiny. After the [FTC's case against Hims over sharing health data with ad platforms](/stories/hims-ftc-data-privacy-lawsuit), investors should ask what consent architecture sits under that dataset.

Allara's model is a paired care team: a women's-health clinician and a registered dietitian treat hormonal, metabolic and reproductive conditions together instead of handing patients between specialists. The company says it has served more than 120,000 women, across PCOS (renamed PMOS, polyendocrine metabolic ovarian syndrome, by an international consensus published in The Lancet in May 2026), thyroid disorders, fertility, postpartum, metabolic health and perimenopause. In 2026 it expanded into GLP-1 medications with nutrition support, hormone replacement therapy, prescription skincare and hair-loss treatment, plus virtual urgent care for BV, UTIs and STI testing. It is in-network with major insurers in most states. Most revenue comes from insurance reimbursement for visits, with cash-pay services, prescriptions and supplements on top, and the company is adding employer and health-system distribution.

The company's own figures (self-reported, not peer-reviewed): in a survey of more than 1,600 new members, 58% had already seen two or more providers about their symptoms, and 80% of those said they had been dismissed or minimised. Among members with irregular cycles, 69% reported more regular cycles. Founder and CEO Rachel Blank, who says a PCOS diagnosis in her 20s took about three years, plans to use the money to put AI tools across the patient journey "from intake to ongoing treatment management" and to build "one of the largest datasets in women's health."

Sources

Update — 2026-10-14

Initial entry — story first created.